TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Researchers at the University Hospital of Bonn and the University of Bonn directly reprogrammed human red blood cell precursors into neural stem cells in laboratory conditions. The cells’ epigenetic clocks shifted toward a younger age, including a reported change from about 80 years to under 20; the work is a cell-reprogramming study, not a treatment for people.
Researchers in Bonn have directly converted human red blood cell precursors into neural stem cells in laboratory conditions and observed a gradual reset in the cells’ epigenetic age markers. The study, published in Aging Cell, reports that cells from an 80-year-old donor had a measured molecular age of less than 20 after reprogramming; it does not show that a person’s body or brain was rejuvenated.
The team from the University Hospital of Bonn and the University of Bonn used transcription factors to redirect blood-cell precursors toward a neural stem-cell identity. Unlike a commonly used two-stage route, the approach converted the cells directly, without first turning them into pluripotent stem cells, which can develop into many cell types.
The researchers assessed age using epigenetic clocks, which track age-associated DNA modifications affecting how genes are read rather than changes to the DNA sequence itself. The report says those clock readings shifted substantially during reprogramming. The change was not immediate: the team followed the process for more than 100 days, describing rejuvenation as gradual.
The findings are reported in the paper “Protracted Fate Acquisition and Epigenetic De-Aging During Induced Neural Stem Cell Conversion of Human Blood Cells,” by Berg and colleagues. The study’s focus was the relationship between cell-fate conversion and age-associated molecular markers, rather than testing a therapy or measuring health outcomes in people.
A Window Into Cellular Age Reset
The work matters because the slower conversion provides researchers with a way to observe how cell identity and epigenetic age change over time. The Bonn team says this could help investigators test which factors or substances speed up or slow down the process. That may add detail to research on how cellular reprogramming works, rather than simply showing an end result.
The authors also point to neuroscience as a relevant field. Age is a major risk factor for neurodegenerative diseases, including Alzheimer’s disease, according to the researchers. But the experiment does not demonstrate prevention or treatment of Alzheimer’s or any other condition. Neural stem cells made in a laboratory are not equivalent to restoring young function in an aging brain, and clinical usefulness remains unestablished.
As an affiliate, we earn on qualifying purchases.
Direct Conversion Without a Pluripotent Stage
Most cells in the body share the same genetic material but acquire different roles as they develop. In laboratory reprogramming, researchers use transcription factors to alter which genetic instructions a cell follows, changing its identity. Earlier work on cell rejuvenation often used two steps: first making a pluripotent stem cell and then directing it toward a particular cell type.
The Bonn study instead converted blood-cell precursors directly into neural stem cells. The research team had previously reported that nerve cells produced through related methods could form connections with existing neurons after transplantation into mouse brains. That earlier animal finding is separate from the current study and does not establish safety or benefit in humans.
The new paper appeared in Aging Cell in 2026. Its central distinction is the reported protracted, trackable process: the epigenetic clock readings changed over weeks, giving researchers more time to examine the steps involved than a rapid two-stage procedure would provide.
““We have directly converted red blood cell precursors into neural stem cells.””
— Prof. Oliver Brüstle, director of the Institute of Reconstructive Neurobiology at the University Hospital of Bonn
As an affiliate, we earn on qualifying purchases.
What the Lab Result Cannot Show
The report describes changes in molecular age markers in cultured cells. It does not establish that the cells regained every feature of younger cells, that the clock shift lasts, or that the process would be safe or effective in a living person. The article says the researchers consider epigenetic rejuvenation to affect how cells behave, but the supplied material does not detail the full range of functional tests or their results.
Details such as the number of donors, the size of the experiments, and how consistently the age-marker shift occurred across samples are not provided in the report excerpt. The findings also do not show that the lab-made neural stem cells can be used to treat patients. Any clinical application would require further research and safety testing.
As an affiliate, we earn on qualifying purchases.
Testing the Reprogramming Timeline
The immediate research opportunity is to use the slow conversion process as an experimental model. The Bonn researchers say they can investigate which factors and active substances alter the pace of epigenetic-clock changes. The published study establishes the reported laboratory finding; the supplied material does not announce a clinical trial or a schedule for human treatment research.
Further work would need to clarify how robust the result is across donors, what biological changes accompany the clock readings, and whether the converted cells retain useful neural stem-cell functions over time. Until such evidence is available, the finding should be understood as early-stage cell biology research, not a method for rejuvenating people.
As an affiliate, we earn on qualifying purchases.
Key Questions
What did the Bonn researchers do?
They used transcription factors to convert human red blood cell precursors directly into neural stem cells in laboratory conditions, then tracked age-associated epigenetic markers during the process.
What does “molecular age under 20” mean?
The report says cells from an 80-year-old donor had an epigenetic clock reading of less than 20 years after reprogramming. That is a measurement of age-associated molecular markers, not a claim that the donor or their body became younger.
Does this study offer a treatment for Alzheimer’s disease?
No. The study describes a laboratory cell-reprogramming result. It does not report a treatment, clinical trial, or demonstrated benefit for people with Alzheimer’s disease.
Why is the gradual process useful to researchers?
The team says the change unfolded over more than 100 days, allowing researchers to follow the resetting of epigenetic clocks and investigate factors that may speed it up or slow it down.
What remains unknown?
The report does not establish how consistently the result applies across donors, how long the marker changes last, or whether the cells are safe and effective for any medical use. Those questions require further research.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
